Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: INC B007839; INCB 7839

Latest Information Update: 19 Oct 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Amides; Antineoplastics; Cyclopropanes; Esters; Piperazines; Piperidines; Small molecules; Spiro compounds
  • Mechanism of Action ADAM10 protein inhibitors; Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 07 Jun 2010 Efficacy and adverse events data from a phase I/II trial in Breast cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 13 Dec 2009 Efficacy, adverse events, pharmacocynamics and pharmacokinetics data from a phase I/II trial in breast cancer presented at the 32nd San Antonio Breast Cancer Symposium (SABCS-2009) ,
  • 26 Feb 2008 Phase-II clinical trials in Breast cancer (monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top